URGN
UroGen Pharma LtdNASDAQ
Healthcare • Biotechnology
Factor tilt: Small-Cap Growth
$24.75-3.81%
Close Nov 6, 2026
- Market cap
- $1.21B
- 1 month
- -33.1%
- 3 months
- -46.6%
- 1 year
- +28.2%
- 52-week range
- $17.00$50.29
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- $0.10Quarter to Sep 30, 2026 · 6 analysts · revenue $89.91M · +5.8% in 30d
- Short interest
- 12.9% of float5.6M shares · settled Oct 15, 2026 · -27.8% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $188.73M
- Net income
- -$97.64M
- Free cash flow
- -$159.14M
- Book value
- —
- Total debt
- $196.13M
- P/E
- —
- Price / sales
- 6.4×
- Price / book
- —
- FCF yield
- -13.2%
- Net margin
- -51.7%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.
Read more
It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
- Website
- urogen.com
- Headquarters
- Princeton, NJ, United States
- Employees
- 300
- Listed
- May 4, 2017
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 23, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 5, 2026 | $72.5M | +199.2% | 90.9% | $111.0K | -$14.4M |
| Mar 2026filed May 6, 2026 | $51.0M | +151.6% | 91.9% | -$20.3M | -$23.6M |
| Dec 2025filed Mar 2, 2026 | $37.8M | +54.0% | 91.3% | -$19.1M | -$26.4M |
| Sep 2025filed Nov 6, 2025 | $27.5M | +9.0% | 88.1% | -$27.4M | -$33.3M |
| Jun 2025filed Aug 7, 2025 | $24.2M | +10.8% | 85.3% | -$41.4M | -$49.9M |
| Mar 2025filed May 12, 2025 | $20.3M | +7.8% | 88.5% | -$36.9M | -$43.8M |
| Dec 2024filed Mar 10, 2025 | $24.6M | +4.4% | 89.9% | -$27.7M | -$37.5M |
| Sep 2024filed Nov 6, 2024 | $25.2M | +20.9% | 90.3% | -$17.5M | -$23.7M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 2, 2026 | $109.8M | +21.4% | 88.7% | -$124.9M | -$153.5M |
| Dec 2024filed Mar 10, 2025 | $90.4M | +9.3% | 90.2% | -$96.8M | -$126.9M |
| Dec 2023filed Mar 14, 2024 | $82.7M | +28.5% | 88.7% | -$65.5M | -$102.2M |
| Dec 2022filed Mar 24, 2023 | $64.4M | +34.0% | 88.1% | -$79.0M | -$109.8M |
| Dec 2021filed Mar 21, 2022 | $48.0M | +307.2% | 89.3% | -$92.3M | -$110.8M |
| Dec 2020filed Mar 18, 2021 | $11.8M | +65,450.0% | 91.4% | -$126.7M | -$128.5M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched URGN. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
5,607,261 shares short
-2,159,657 shares (-27.8%) vs Sep 30, 2026
12.9% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
7,766,918 shares short
+1,519,420 shares (+24.3%) vs Sep 15, 2026
17.9% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
6,247,498 shares short
+2,111 shares (0%) vs Aug 31, 2026
14.5% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
6,245,387 shares short
+1,124,980 shares (+22%) vs Aug 14, 2026
14.5% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
5,120,407 shares short
+531,298 shares (+11.6%) vs Jul 31, 2026
11.9% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
4,589,109 shares short
-1,100,275 shares (-19.3%) vs Jul 15, 2026
10.6% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind URGN’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if URGN is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
43 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 22, 2026
Smart-money 13F trend: distributing (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 29 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
190 filers reported a long position in URGN for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
55.2%
of the 42.4M shares 13-F filers reported
Moves vs Q1 2026
6 added0 trimmed
1 new · 3 unchanged
Net shares held
+5.8%
across the 9 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | $167.2M · 4.5M shares | 4.5M | Unchanged |
| 2 | BlackRock, Inc. | $117.8M · 3.2M shares | 3.2M | +12.5% |
| 3 | MORGAN STANLEY | $94.8M · 2.6M shares | 2.6M | +0.6% |
| 4 | Kynam Capital Management, LP | $89.6M · 2.4M shares | 2.4M | +8.3% |
| 5 | Jefferies Financial Group Inc. | $80.9M · 2.2M shares | 2.2M | Unchanged |
| 6 | SG Americas Securities, LLC | $75.5M · 2.1M shares | 2.1M | +23.8% |
| 7 | AMERICAN CENTURY COMPANIES INC | $62M · 1.7M shares | 1.7M | +2.9% |
| 8 | ACORN CAPITAL ADVISORS, LLC | $61.6M · 1.7M shares | 1.7M | Unchanged |
| 9 | Point72 Asset Management, L.P. | $56.1M · 1.5M shares | 1.5M | New |
| 10 | FRONTIER CAPITAL MANAGEMENT CO LLC | $55.5M · 1.5M shares | 1.5M | +14.8% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of URGN file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Oct 27, 2026 | BlackRock, Inc.13G · passive · amended | 6.3% |
| Aug 12, 2026 | TORONTO DOMINION BANK13G · passive · amended | 6.7% |
| May 15, 2026 | Paradigm Biocapital Advisors LP13G · passive · amended | 3.5%under 5% |
Get the Full Analysis for URGN
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.